Skip to main content

Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
non-liposomal doxorubicin
pegylated liposomal doxorubicin
Description

In this report, we report counts and baseline characteristics of users of pegylated liposomal doxorubicin and its chosen comparator, non-liposomal doxorubicin, in the Sentinel Distributed Database (SDD). The study period includes data from January 1, 2011 to June 30, 2018. We distributed this request to 17 Sentinel Data Partners on September 26, 2018.

Deliverables (1)
Sentinel Modular Program Report: Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
January 1, 2011 - June 30, 2018
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)